Changes in Debrisoquine Hydroxylation Capacity Following Liver Surgery

Abstract

Liver transplantation or the surgical construction of portacaval shunts may radically alter an individual's debrisoquine hydroxylation capacity. Good clinical management should encompass a full awareness of such changing needs and problems in patients who undergo hepatic surgery.

Get full access to this article

View all access options for this article.

References

Mahgoub A. , Idle JR , Dring LC , Lancaster R. & Smith RL Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584-86.

Kimura S. , Umeno M. , Skoda RC , Meyer UA & Gonzalez FJ The human debrisoquine 4-hydroxylase (CYP2D) locus sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. American Journal of Human Genetics 1989; 45: 889-905.

Cholerton S. , Daly AK & Idle JR The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends in Pharmacological Science, 1992; 13: 434-9.

Eichelbaum M. & Gross AS The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects . In Pharmacogenetics of Drug Metabolism. Kalow W (ed), 1992; Pergamon Press Inc: New York, pp. 625-48.

Ayesh R. & Smith RL Genetic polymorphism in human toxicology. In Recent Advances in Clinical Pharmacology and Toxicology. Turner P & Volans GN (eds), 1989; Churchill Livingstone, 4: 137-57.

Pugh Rnh , Murray-Lyon IM , Dawson JL , Pietroni MC & Williamson R. Transection of the oesophagus for bleeding oesophageal varices. British Journal of Surgery 1973; 60: 646-9.

Hobscher SG , Clements D. , Elias E. & McMaster P.

Biopsy findings in cases of rejection of liver allograft. Journal of Clinical

Pathology 1985; 38: 1366-73.

Calne RY , McMaster P. , Portmann B. , Wall WJ & Williams R. Observations on preservation, bile drainage and rejection in 64 human orthotopic liver grafts. Annals of Surgery 1977; 186: 282-90.

Idle JR , Mahgoub A. , Angelo MM , Dring LG , Lancaster R. & Smith RL The metabolism of [14C]-debrisoquine in man. British Journal of Clinical Pharmacology 1979; 7: 257-66.

10.

Sloan TP Properties of oxidation polymorphism in man with particular reference to the disposition of debrisoquine, phenacetin and phenytoin. Ph.D. Thesis, 1980, University of London, England, UK.

11.

Evans Dap , Mahgoub A. , Sloan TP , Idle JR & Smith RL

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. Journal of Medical

Genetics 1980; 17: 102-5.

12.

Evans Dap , Harmer D. , Downham DY , Whibley EJ , Idle JR , Ritchie J. & Smith RL

The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. Journal of Medical

Genetics 1983; 20: 321-9.

13.

Mitchell SC & Haley CS

Debrisoquine hydroxylation phenotyping: do we expect too much?

Lancet 1990; 2: 694.

14.

Idle JR Poor metabolisers of debrisoquine reveal their true colours. Lancet 1989; 2: 1097.

15.

Lanthier PL , Reshef R. , Shah RR , Oates NS , Smith RL & Morgan MY Oxidation phenotyping in alcoholics with liver disease of varying severity. Alcoholism ( N.Y.) 1984; 8: 435-41.

16.

Bertilsson L. , Dahl ML , Sjoqvist F. , Aberg-Wistedt A. , Humble M. , Johansson I. , Lundqvist E. & Ingelman-Sundberg M. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341: 63.